Our database analyses revealed that ATP13A2 is expressed to similar levels as ATP13A3 in neuroblastoma patients and, contrary to ATP13A3 and SLC3A2 expression, high expression of ATP13A2 is predictive of a better outcome in patients. This evidence concerns the gene SLC3A2 and neuroblastoma.